MIRDAMETINIB 391210-10-9Chemical Formula: C16H14F3IN2O4Molecular Weight: 482.19 PD0325901; PD 0325901; PD-325901; mirdametinib FDA APPROVED 2/11/2025, Gomekli, To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection  IUPAC/Chemical Name: (R)-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide SpringWorks Therapeutics (a spin out of Pfizer ) is developing mirdametinib, a second-generation, non-ATP competitive, allosteric MEK1 and MEK2 inhibitor derived from CI-1040, … Continue reading MIRDAMETINIB